Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Champions Oncology (CSBR) Shares Outstanding (2016 - 2026)

Champions Oncology has reported Shares Outstanding over the past 16 years, most recently at $13.9 million for Q1 2026.

  • For Q1 2026, Shares Outstanding changed 0.44% year-over-year to $13.9 million; the TTM value through Jan 2026 reached $13.9 million, changed 0.44%, while the annual FY2025 figure was $13.8 million, 0.46% changed from the prior year.
  • Shares Outstanding for Q1 2026 was $13.9 million at Champions Oncology, down from $14.0 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $14.0 million in Q4 2025 and troughed at $13.5 million in Q3 2023.
  • A 5-year average of $13.7 million and a median of $13.6 million in 2023 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: dropped 0.28% in 2023 and later increased 1.71% in 2025.
  • Year by year, Shares Outstanding stood at $13.6 million in 2022, then rose by 0.26% to $13.6 million in 2023, then rose by 1.66% to $13.8 million in 2024, then increased by 1.36% to $14.0 million in 2025, then fell by 0.86% to $13.9 million in 2026.
  • Business Quant data shows Shares Outstanding for CSBR at $13.9 million in Q1 2026, $14.0 million in Q4 2025, and $13.9 million in Q3 2025.